Rare diseases
Investigational molecules
Locations
BMS-986517 is an investigational protein-based substance being developed by Bristol-Myers Squibb International Corporation.[1] It has no marketing authorisation in the product records, meaning it is not yet an approved medicine.[1] The substance is classified under the therapeutic area of neoplasms (cancers).[1]
BMS-986517 is a protein-based substance of the type "Protein - Other".[1] It is an investigational medicine, which means it is still being tested in clinical trials and has not been approved for use outside of research.[1] The product records list BMS-986517 as the only name for this substance.[1] The company responsible for the product is Bristol-Myers Squibb International Corporation.[1]
The available registry data do not describe the specific mechanism of action of BMS-986517. As a protein-based substance, it belongs to a category of medicines that are typically designed to interact with specific targets in the body, but no further details on how it works are provided in the trial record.[1]
BMS-986517 is given as a solution for infusion, administered by intravenous use (into a vein).[1] In the trial, it is being tested alone and in combination with another investigational medicine called BNT327, which is also given by intravenous infusion.[1]
There is one clinical trial of BMS-986517 in the registry: a Phase 1/2a, first-in-human study in participants with advanced solid tumors.[1] The trial is authorised and plans to enrol 58 participants.[1] The study is divided into two parts: Part 1 aims to find safe doses of BMS-986517 given alone or in combination with an investigational medicine, and Part 2 checks whether the chosen doses continue to be safe for people with specific cancers.[1] The main thing the trial measures is how often side effects called dose-limiting toxicities happen, as well as how often side effects, serious side effects, side effects causing treatment to stop, or deaths occur.[1]
The trial is open to participants with advanced solid tumors.[1] Further details about specific inclusion and exclusion criteria are not provided in the registry record.[1]
No information on side effects is available from the provided sources. The trial is designed to monitor side effects, including dose-limiting toxicities, serious side effects, and side effects that cause treatment to stop, but no results have been reported yet.[1]
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
